Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Connective tissue growth factor antibodies
US9034643B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9034643-B2 |
| Application number | US-201213691356-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2012 |
| Priority date | Jun 4, 2003 |
| Publication date | May 19, 2015 |
| Grant date | May 19, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
First claim
Opening claim text (preview).
What is claimed is: 1. A polynucleotide sequence comprising a sequence selected from the group consisting of: (a) a polynucleotide sequence encoding SEQ ID NO:14; (b) a polynucleotide sequence encoding from amino acid 1 through amino acid 167 of SEQ ID NO:14; (c) SEQ ID NO:13; and (d) nucleotide 1 through nucleotide 501 of SEQ ID NO:13. 2. A recombinant polynucleotide comprising the polynucleotide sequence of claim 1 operably linked to a vector sequen…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9034643B2 cover?
- The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
- Who is the assignee on this patent?
- Fibrogen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).